摘要
目的研究罗沙司他在维持性腹膜透析患者肾性贫血治疗中的应用效果。方法将2019年1月—2021年10月于泰州市第二人民医院进行维持性腹膜透析的84例肾性贫血患者采用随机数表法分为对照组(42例)和研究组(42例)。对照组采用促红细胞生成素治疗,研究组采用罗沙司他治疗,分析两组的临床疗效、治疗前后的贫血指标和不良反应发生情况。结果研究组治疗总有效率为95.24%,优于对照组的80.95%,差异有统计学意义(χ^(2)=4.087,P<0.05)。治疗前两组患者的血细胞比容(HCT)、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)指标对比,差异无统计学意义(P>0.05);治疗后研究组患者的HCT(29.02±2.39)%、SF(270.04±40.05)μg/L、TSAT(33.64±1.57)%均优于对照组,差异有统计学意义(t=5.808、4.450、21.312,P<0.05)。研究组患者的不良反应发生率为16.67%,低于对照组患者的35.71%,差异有统计学意义(χ^(2)=3.941,P<0.05)。结论罗沙司他具有更理想的治疗效果,能够改善患者的贫血症状,纠正患者贫血的相关指标,进而促进患者整体的治疗效果,降低不良反应发生率,抑制患者炎性症状的发展,并且具有较高的安全性。
Objective To study the effect of roxadustat in the treatment of renal anemia in patients with maintenance peritoneal dialysis.Methods A total of 84 patients with renal anemia who underwent maintenance peritoneal dialysis in Taizhou Second People's Hospital from January 2019 to October 2021 were randomly divided into the control group(42 cases)and the study group(42 cases).The control group was treated with erythropoietin,and the study group was treated with roxadustat.The clinical efficacy,anemia indexes before and after treatment and adverse reac⁃tions were analyzed.Results The total effective rate of the study group was 95.24%,which was better than 80.95%of the control group,and the difference was statistically significant(χ^(2)=4.087,P<0.05).Before treatment,there was no statistically significant difference in hematocrit(HCT),serum ferritin(SF),transferrin saturation(TSAT)between the two groups(P>0.05);after treatment,HCT(29.02±2.39)%,SF(270.04±40.05)μg/L,TSAT(33.64±1.57)%in the study group were better than those of the control group,and the difference was statistically significant(t=5.808,4.450,21.312,P<0.05).The incidence of adverse reactions in the study group was 16.67%,which was lower than 35.71%in the control group,and the difference was statistically significant(χ^(2)=3.941,P<0.05).Conclusion Roxadus⁃tat has a more ideal therapeutic effect,which can improve the symptoms of anemia and correct the related indicators of anemia in patients.This further promotes the overall therapeutic effect of the patient,reduces the incidence of ad⁃verse reactions,inhibits the development of the patient's inflammatory symptoms,and has high safety.
作者
丁静明
高卫臻
黄子华
华丽
DING Jingming;GAO Weizhen;HUANG Zihua;Hua Li(Department of Nephrology,Taizhou Second People's Hospital,Taizhou,Jiangsu Province,225500 China)
出处
《系统医学》
2022年第11期71-74,共4页
Systems Medicine
关键词
罗沙司他
维持性腹膜透析
肾性贫血
临床效果
Roxadustat
Maintenance peritoneal dialysis
Renal anemia
Clinical effect
